modelNifedipineCombinations
Extends from Pharmacolibrary.Drugs.ATC.C.C08CA55.
Information
| name: | NifedipineCombinations | |
| ATC code: | C08CA55 | route: | oral |
| compartments: | 2 | |
| dosage: | 20 | mg |
| volume of distribution: | 70 | L |
| clearance: | 24 | L/h |
| other parameters in model implementation | ||
Nifedipine is a dihydropyridine calcium channel blocker used to treat hypertension and angina pectoris. It works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to vasodilation and decreased blood pressure. Combinations may be used clinically, typically alongside other antihypertensive or antianginal agents. Nifedipine-containing combinations are approved and currently used in clinical practice for cardiovascular conditions.
Pharmacokinetics
Estimated population pharmacokinetic parameters for oral nifedipine in healthy adult subjects, as there are no available published data specific for ATC code C08CA55 combinations. The values are based on well-established typical pharmacokinetics of nifedipine immediate-release administered orally.
References
Brown, RS, et al., & Bottomley, WK (1991). On the mechanism of drug-induced gingival hyperplasia. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20(5) 201–209. DOI:10.1111/j.1600-0714.1991.tb00419.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/1648612
Plosker, GL, & Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 22(6) 389–411. DOI:10.2165/00019053-200422060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15099124
Patel, N, et al., & Turner, DB (2014). Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 57 240–249. DOI:10.1016/j.ejps.2013.09.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24060671
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.TransferRate | ka (from PK_2C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_2C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)